Pulmonary eosinophilia

This study follows 335 adults with severe eosinophilic asthma who are taking benralizumab. Researchers want to see if the drug helps patients achieve partial or complete clinical remission—meaning fewer symptoms, no need for steroid pills, and better lung function—over 12 to 24 m…

This study follows 300 adults with severe eosinophilic asthma who are prescribed benralizumab as part of their normal care in Germany. Researchers will track changes in asthma control, lung function, and medication use over one year. The goal is to see how the drug performs outsi…

This study tests a new injectable drug called depemokimab in 30 children aged 6 to 11 with asthma that involves a specific type of inflammation. The drug is given alongside their usual asthma medicines to see how the body processes it, how well it works, and if it is safe. The go…

This study tests an oral drug called KT-621 in 264 adults with moderate to severe eosinophilic asthma that is not well controlled by current treatments. Participants will take either KT-621 or a placebo daily for several weeks. Researchers will measure changes in lung function an…

This phase 3 trial is testing whether adding benralizumab (an injectable drug) to medium-dose inhalers can reduce asthma attacks in people with eosinophilic asthma whose symptoms are not well controlled. About 400 participants aged 12 to 75 will be randomly assigned to receive be…

This study tests an experimental drug called SIM0718 for people with asthma that is not well controlled by current inhalers. About 418 adults and teens aged 12 to 75 will receive either the drug or a placebo for one year. The main goal is to see if the drug reduces the number of …